Attached files
| file | filename |
|---|---|
| EX-10.16 - EX-10.16 - Karyopharm Therapeutics Inc. | d282276dex1016.htm |
| EX-32.1 - EX-32.1 - Karyopharm Therapeutics Inc. | d282276dex321.htm |
| EX-31.2 - EX-31.2 - Karyopharm Therapeutics Inc. | d282276dex312.htm |
| EX-31.1 - EX-31.1 - Karyopharm Therapeutics Inc. | d282276dex311.htm |
| EX-21.1 - EX-21.1 - Karyopharm Therapeutics Inc. | d282276dex211.htm |
| EX-12.1 - EX-12.1 - Karyopharm Therapeutics Inc. | d282276dex121.htm |
| 10-K - FORM 10-K - Karyopharm Therapeutics Inc. | d282276d10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-201366) of Karyopharm Therapeutics Inc., |
| (2) | Registration Statement (Form S-3 No. 333-214489) of Karyopharm Therapeutics Inc., |
| (3) | Registration Statement (Form S-8 No. 333-194746) pertaining to the 2010 Stock Incentive Plan, 2013 Stock Incentive Plan, and 2013 Employee Stock Purchase Plan of Karyopharm Therapeutics Inc., |
| (4) | Registration Statement (Form S-8 No. 333-202742) pertaining to the 2013 Stock Incentive Plan of Karyopharm Therapeutics Inc., and |
| (5) | Registration Statement (Form S-8 No. 333-210221) pertaining to the 2013 Stock Incentive Plan of Karyopharm Therapeutics Inc.; |
of our report dated March 16, 2017, with respect to the consolidated financial statements of Karyopharm Therapeutics Inc. included in this Annual Report (Form 10-K) of Karyopharm Therapeutics Inc. for the year ended December 31, 2016.
| /s/ Ernst & Young LLP |
Boston, Massachusetts
March 16, 2017